Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3981314 · 1 trial · 1 indication
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3981314 Part A | EXPERIMENTAL | Single-ascending doses of LY3981314 administered subcutaneously (SC) |
| LY3981314 Part B | EXPERIMENTAL | Single dose of LY3981314 administered SC |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered SC |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3981314 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead electrocardiogram (ECG) * Individuals assigned male at birth who agree to follow contraceptive requirements, or individuals assig...
LY3981314 is an investigational small molecule developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with a single active trial evaluating it in healthy adult participants. The specific therapeutic indication for LY3981314 has not been disclosed.
LY3981314 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study of LY3981314 in healthy participants.
LY3981314 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial of LY3981314 is currently active, and no trials of the drug have been completed.
LY3981314 is being studied in one Phase 1 trial, NCT07005284, titled A Study of LY3981314 in Healthy Participants. The trial is active but not recruiting, is placebo-controlled and double-blind, and has an enrollment of 76 participants in the United States.
The Phase 1 trial of LY3981314, NCT07005284, is a randomized, double-blind, placebo-controlled study in healthy volunteers. It enrolled 76 participants aged 18 years and older of all sexes and is being conducted in the United States. The trial is active but not recruiting.